Axsome Therapeutics (AXSM) News Today → Do you know the 3 golden rules for dividend investing? (From DTI) (Ad) Free AXSM Stock Alerts $71.80 -2.10 (-2.84%) (As of 06/10/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 10 at 12:35 PM | marketbeat.comLighthouse Investment Partners LLC Invests $4.47 Million in Axsome Therapeutics, Inc. (NASDAQ:AXSM)Lighthouse Investment Partners LLC purchased a new position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 56,202 shares of the comJune 7 at 1:48 AM | americanbankingnews.comAxsome Therapeutics (NASDAQ:AXSM) Given New $130.00 Price Target at Royal Bank of CanadaJune 6, 2024 | americanbankingnews.comAxsome Therapeutics' (AXSM) "Buy" Rating Reiterated at HC WainwrightJune 6, 2024 | marketbeat.comAxsome Therapeutics (NASDAQ:AXSM) Rating Reiterated by HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $190.00 price objective on shares of Axsome Therapeutics in a research note on Thursday.June 5, 2024 | marketbeat.comRoyal Bank of Canada Boosts Axsome Therapeutics (NASDAQ:AXSM) Price Target to $130.00Royal Bank of Canada upped their price objective on shares of Axsome Therapeutics from $127.00 to $130.00 and gave the company an "outperform" rating in a report on Wednesday.June 5, 2024 | marketbeat.com50,000 Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) Bought by Affinity Asset Advisors LLCAffinity Asset Advisors LLC purchased a new position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 50,000 shares of the cJune 5, 2024 | globenewswire.comAxsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem LaboratoriesJune 4, 2024 | marketbeat.comRhenman & Partners Asset Management AB Buys 39,000 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)Rhenman & Partners Asset Management AB boosted its stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 97.3% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 79,100 shares of the company's stock afteJune 4, 2024 | globenewswire.comAxsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness MonthJune 4, 2024 | americanbankingnews.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Average Rating of "Moderate Buy" from BrokeragesMay 31, 2024 | americanbankingnews.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Director Mark Coleman Sells 5,249 SharesMay 30, 2024 | insidertrades.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Director Sells $394,777.29 in StockMay 29, 2024 | marketbeat.comInsider Selling: Axsome Therapeutics, Inc. (NASDAQ:AXSM) Director Sells 5,249 Shares of StockAxsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) Director Mark Coleman sold 5,249 shares of the stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $75.21, for a total transaction of $394,777.29. Following the completion of the sale, the director now owns 19,848 shares in the company, valued at $1,492,768.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.May 29, 2024 | globenewswire.comAxsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024May 28, 2024 | finance.yahoo.comAxsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of Clinical Psychopharmacology Annual (ASCP) MeetingMay 25, 2024 | marketbeat.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Sold by Victory Capital Management Inc.Victory Capital Management Inc. lessened its holdings in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 72.5% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 5,208 shares of the company's stock after selling 13,726May 22, 2024 | marketbeat.comStock Traders Buy High Volume of Call Options on Axsome Therapeutics (NASDAQ:AXSM)Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) was the recipient of unusually large options trading on Wednesday. Stock investors bought 5,695 call options on the company. This is an increase of 483% compared to the typical volume of 977 call options.May 20, 2024 | markets.businessinsider.comHold Rating on Axsome Therapeutics Amidst Regulatory Strategy and Commercialization ProspectsMay 20, 2024 | marketbeat.comNational Bank of Canada FI Has $46,000 Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)National Bank of Canada FI cut its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 99.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 600 shares of the company's stock afterMay 19, 2024 | marketbeat.comSwiss National Bank Has $4.82 Million Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)Swiss National Bank decreased its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 15.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 60,500 shares of the company's stock after selling 11,May 18, 2024 | fool.com3 Monster Stocks in the Making You Can Buy Right NowMay 17, 2024 | finance.yahoo.comAxsome Therapeutics, Inc. (AXSM)May 15, 2024 | marketbeat.comNicholas Investment Partners LP Sells 312,335 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)Nicholas Investment Partners LP lessened its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 79.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 82,645 shares of the company's stock after sMay 13, 2024 | finance.yahoo.com15 Most Depressed States in the USMay 11, 2024 | investorplace.comThe 3 Most Undervalued Biotech Stocks to Buy in May 2024May 11, 2024 | fool.comPrediction: These 2 Growth Stocks Could Triple By 2030May 11, 2024 | marketbeat.com21,086 Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) Acquired by Truist Financial CorpTruist Financial Corp purchased a new stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 21,086 shares of the company's stock, valued at approximateMay 10, 2024 | marketbeat.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) to Post Q2 2024 Earnings of ($1.31) Per Share, HC Wainwright ForecastsAxsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Investment analysts at HC Wainwright lowered their Q2 2024 earnings estimates for Axsome Therapeutics in a research note issued on Tuesday, May 7th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per shaMay 10, 2024 | seekingalpha.comWhy Axsome Therapeutics Is A Promising Stock Pick In CNS TreatmentsMay 9, 2024 | finance.yahoo.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This YearMay 9, 2024 | marketbeat.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) to Post Q3 2025 Earnings of $0.47 Per Share, HC Wainwright ForecastsAxsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Analysts at HC Wainwright dropped their Q3 2025 EPS estimates for shares of Axsome Therapeutics in a report released on Tuesday, May 7th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of $0.47 fMay 8, 2024 | marketbeat.comAxsome Therapeutics (NASDAQ:AXSM) Price Target Lowered to $106.00 at MizuhoMizuho lowered their price target on shares of Axsome Therapeutics from $109.00 to $106.00 and set a "buy" rating on the stock in a report on Wednesday.May 8, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Axsome Therapeutics Amidst Strong Q1 Earnings and Promising Clinical TrialsMay 8, 2024 | marketbeat.comFY2026 EPS Estimates for Axsome Therapeutics, Inc. Reduced by Analyst (NASDAQ:AXSM)Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Investment analysts at Leerink Partnrs reduced their FY2026 earnings per share (EPS) estimates for Axsome Therapeutics in a report released on Monday, May 6th. Leerink Partnrs analyst M. Goodman now anticipates that the company will earn $1.May 8, 2024 | globenewswire.comAxsome Therapeutics to Present at Upcoming Investor ConferencesMay 7, 2024 | marketbeat.comAxsome Therapeutics (NASDAQ:AXSM) PT Lowered to $125.00Citigroup cut their target price on Axsome Therapeutics from $127.00 to $125.00 and set a "buy" rating on the stock in a research note on Tuesday.May 7, 2024 | markets.businessinsider.comBuy Rating Affirmed on Axsome Therapeutics Amid Strong Sales and Strategic PositioningMay 7, 2024 | finance.yahoo.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Q1 2024 Earnings Call TranscriptMay 7, 2024 | marketbeat.comRobert W. Baird Boosts Axsome Therapeutics (NASDAQ:AXSM) Price Target to $112.00Robert W. Baird boosted their price target on Axsome Therapeutics from $108.00 to $112.00 and gave the stock an "outperform" rating in a research report on Tuesday.May 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Axsome Therapeutics on Strong Auvelity Sales and Market Expansion PotentialMay 7, 2024 | finance.yahoo.comAxsome Therapeutics Inc (AXSM) (Q1 2024) Earnings Call Transcript Highlights: Soaring Revenues ...May 7, 2024 | finance.yahoo.comQ1 2024 Axsome Therapeutics Inc Earnings CallMay 6, 2024 | fool.comAxsome Therapeutics (AXSM) Q1 2024 Earnings Call TranscriptMay 6, 2024 | investorplace.comAXSM Stock Earnings: Axsome Therapeutics Beats EPS, Beats Revenue for Q1 2024May 6, 2024 | washingtonpost.comAxsome: Q1 Earnings SnapshotMay 6, 2024 | msn.comAxsome Therapeutics GAAP EPS of -$1.44 misses by $0.21, revenue of $75M beats by $2.15MMay 6, 2024 | globenewswire.comAxsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 2, 2024 | stocknews.comInvestors Beware of These 3 Pharma StocksMay 2, 2024 | marketbeat.comCannell & Co. Lowers Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)Cannell & Co. lowered its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 20.5% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 82,845 shares of the company's stock after selling 21,345 shares during the period. CannellMay 1, 2024 | globenewswire.comAxsome Therapeutics Recognizes May as Mental Health Awareness Month Get Axsome Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter. Email Address Alert: Your Bank is Dying – Act Now or Lose Everything! (Ad)Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow. Click here for your free guide AXSM Media Mentions By Week AXSM Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AXSM News Sentiment▼0.770.76▲Average Medical News Sentiment AXSM News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AXSM Articles This Week▼126▲AXSM Articles Average Week Get Axsome Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: HRMY News TARO News XNCR News VTRS News UTHR News RDY News SRPT News CTLT News ELAN News ROIV News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AXSM) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersMissed NVDA? Buy this AI stock NOWAfter Nvidia's record-breaking earnings surge, Wall Street is now selling the stock at the fastest pace in sev...Chaikin Analytics | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredMoonshot Coins for the Current Crypto RunDid you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum s...Crypto 101 Media | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...Unstoppable Prosperity | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | Sponsored